Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP).

ABSTRACT:

Purpose

To illustrate the benefits of the extended half-life (EHL) recombinant factor VIII product N8-GP (Esperoct^®, turoctocog alfa pegol) by describing individual cases of patients with severe hemophilia A treated with N8-GP in the pathfinder clinical trial program.

Patients and methods

This manuscript presents selected patient cases from the pivotal pathfinder clinical trial program, which included a number of clinical studies in adults (pathfinder 2 and 3) and children (pathfinder 5); overall results published previously. Clinical data and outcomes described in this manuscript are more detailed and derived from several interesting patient cases (five adults from pathfinder 2 and two children from pathfinder 5), who received N8-GP as prophylaxis (PPX) for their

SUBMITTER: Klamroth R 

PROVIDER: S-EPMC8575374 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature